Insulin degludec/insulin aspart in Japanese patients with type 1 diabetes mellitus: Distinct prandial and basal glucose-lowering effects

What Was Tested

This randomized controlled trial paper looks at Insulin Aspart.

Insulin degludec/insulin aspart (IDegAsp) is a soluble co-formulation of long-acting insulin degludec (IDeg) and rapid-acting insulin aspart (IAsp).

Who Took Part

The study group was 21 patients.

The age groups tagged for this paper are adults and middle-aged adults, both men and women.

How the Study Was Run

The design is described as randomized, double-blind and crossover.

Because people in this Insulin Aspart study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the patients nor the staff measuring them knew who was on Insulin Aspart, so expectations could not easily colour the readings.

In the crossover set-up each of the patients took both Insulin Aspart and the comparison in turn, acting as their own control.

What Was Measured

The subject headings attached to it are Asian People, Biphasic Insulins, Blood Glucose, Diabetes Mellitus, Type 1, Drug Combinations, Glucose and Glucose Clamp Technique.

The authors tagged it with the keywords Insulin degludec - insulin aspart and Japanese.

What This Means in Plain Language

The paper is a randomized, double-blind and crossover study of Insulin Aspart in 21 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2016 (Journal of diabetes investigation), a journal based in Japan.

More context: the Insulin Aspart compound page, all human trials.